Advanced search    

Search: authors:"Daniel Landau"

14 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Changes in the Growth Hormone-IGF-I Axis in Non-obese Diabetic Mice

We investigated the changes in GH-IGF-I axis in non-obese diabetic (NOD)-mice, a model of insulin dependent diabetes mellitus. Diabetic female NOD mice and their age- and sex-matched controls were sacrificed at 4, 14, 21 and 30 days (30d DM) after the onset of glycosuria. Serum GH levels increased and serum IGF-I levels decreased in the 30d DM group (182 ± 32% and 45 ± 24% of age...

Changes in the Growth Hormone-IGF-I Axis in Non-obese Diabetic Mice

We investigated the changes in GH-IGF-I axis in non-obese diabetic (NOD)-mice, a model of insulin dependent diabetes mellitus. Diabetic female NOD mice and their age- and sex-matched controls were sacrificed at 4, 14, 21 and 30 days (30d DM) after the onset of glycosuria. Serum GH levels increased and serum IGF-I levels decreased in the 30d DM group (182 ± 32% and 45 ± 24% of age...

Growth Hormone (GH) Hypersecretion and GH Receptor Resistance in Streptozotocin Diabetic Mice in Response to a GH Secretagogue

The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline. On day 14, blood samples were obtained before and 10 minutes after the injection. Livers were removed and frozen for determination of the mRNA...

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia

File. ARRIVE guidelines checklist (ARRIVE_checklist_Landau_0318.docx). (DOCX) S2 File. Experiments' raw data (Lital_PLOS_raw data_0418.pdf). (PDF) Author Contributions Conceptualization: Daniel Landau ... , Yael Segev. Investigation: Lital London, Inbar Bandach, Yael Segev. Methodology: Lital London, Inbar Bandach, Yael Segev. Validation: Daniel Landau. Writing ? original draft: Daniel Landau. Writing

Case report: severe asymptomatic hyponatremia in Prader-Willi Syndrome

report. (PPTX 76 kb) Competing interests The authors declare that they have no competing interests. Authors’ contributions Daniel Landau, Harry J. Hirsch, and Varda Gross-Tsur each participated in

Impaired renal growth hormone JAK/STAT5 signaling in chronic kidney disease

Background Treatment with recombinant human growth hormone (GH) is the standard therapy for short stature in children with chronic kidney disease (CKD). However, concerns have been raised on the potential renal fibrogenic effects of GH. There is no information regarding the renal GH receptor (GHR)-JAK-STAT signaling pathway in CKD.

Two novel homozygous SLC2A9 mutations cause renal hypouricemia type 2

Background. Elevated serum uric acid (UA) is associated with gout, hypertension, cardiovascular and renal disease. Hereditary renal hypouricemia type 1 (RHUC1) is caused by mutations in the renal tubular UA transporter URAT1 and can be complicated by nephrolithiasis and exercise-induced acute renal failure (EIARF). We have recently shown that loss-of-function homozygous mutations...

Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus

Background. The aim of this study was to describe the urological complications associated with nephrogenic diabetes insipidus (NDI) due to a mutation in aquaporin-2 (AQP2), a collecting-duct protein activated by ADH signalling. Methods. We provide a case series description of a group of seven patients with autosomal recessive NDI due to AQP2 gene mutation, receiving routine...

Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease

Background. The growth hormone (GH)-insulin-like growth factor (IGF)-SST (SST) axis is involved in diabetic nephropathy (DN). We have recently shown a beneficial effect on diabetic kidney disease markers by the use of a novel somatostatin (SST) analogue (PTR-3173) (S). The purpose of this study is to compare the effects of S with a previously used SST analogue (octreotide) and an...

CKD ANAEMIA

Introduction and Aims: Iron deficiency (ID) is common in patients with ND-CKD. Treatment success with oral iron is often limited secondary to decreased absorption in CKD due to inflammation and poor patient adherence due to gastrointestinal side effects and the 2-3X/day oral iron dosing regimen. Randomised trials comparing intravenous (IV) vs oral iron for the treatment of...

The effect of growth hormone on the development of diabetic kidney disease in rats

Background. Nephropathy is the most severe complication of diabetes mellitus. We investigated the effect of exogenous growth hormone (GH) administration on renal function and matrix deposition in the streptozotocin (STZ) model of type I‐diabetic rat. Methods. Adult female STZ‐diabetic rats (D), non‐diabetic control rats injected with saline (C) and control and diabetic rats...

Anaesthetic management of a patient with glycogen storage disease type 1b

Z e ' e v Shenkman Yackov Golub Shimon Meretyk t" Yoram Shir Daniel Landau :I:Ezekiel H. Landau ' Purpose: A rare case of a ten-year old patient with type Ib glycogen storage disease (GSD

CKD BONE DISEASE

Introduction and Aims: In clinical practice it has been reported that hypomagnesaemia is associated to low mineral density. On the other hand in vitro studies have shown that magnesium (Mg) decreases calcification in vascular smooth muscle cells. But the effects of increasing Mg levels on bone homeostasis are poorly understood. Here we elucidate the effects of elevated Mg on the...